TRANSLATIONAL RESEARCH PROGRAMS
A number of pioneering Translational Neuroscience Research Programs have been developed in an interdisciplinary local network by our group at the APMI and APMI-CP initiation site Paris, France, at the Sorbonne University, and the Pitié-Salpêtrière University Hospital ([IM2A] and [ICM]) to organize and integrate the components of systems biology and systems neurophysiology to facilitate the development of Precision Medicine in Alzheimer’s Disease:
(FRA research program level)
PI: H. Hampel, MD, PhD, MSc
Co-PI: S. Lista, PhD
Co-PI: A. Vergallo, MD
“Exploring the Systems Biology and Systems Neurophysiology of Alzheimer’s Disease”
Duration: 5 years
The aim of this research program is to apply the concepts of systems biology and systems neurophysiology to generate quantitative time-dependent pathophysiological trajectories that will allow the identification of individual and subgroup-specific biochemical and neurodynamic disease profiles to accurately chart the biological spectrum of neurodegenerative diseases, focusing on Alzheimer’s Disease, across all stages (preclinical to prodromal to late clinical).
The availability of these outcomes provides the basis to substantially change clinical diagnostic practice and the optimized assessment of treatment efficacy in clinical trials, thus paving the way to the development of precision neurology through customized targeted and biomarker-guided therapies.
“Pathway to Precision Medicine for Alzheimer’s Disease”.
Duration: 5 years
This research program is divided into 2 modules:
“SYNCHRONY” aims at:
1) Defining functional and structural brain connectivity alterations related to APOE profile to determine the genetically-mediated functional and structural network alterations predicting cognitive decline over time in cognitive normal older individuals at risk for Alzheimer’s Disease;
2) Stratifying the aging population along the genetic patterns of SNPs associated to imaging phenotypes, i.e. structural and functional connectivity, and brain atrophy.
Through the SYNCHRONY module, we expect to provide genetic subset of preclinical at risk individuals for Alzheimer’s Disease presenting early structural and functional brain changes leading to neurodegenerative diseases such as Alzheimer’s Disease
“TURBO” aims at:
1) Developing a staging model of Alzheimer’s Disease in the INSIGHT-preAD cohort. Such a biological and neurophysiological staging system is necessary for the characterization of the preclinical stage of Alzheimer’s Disease and for developing “targeted” treatment strategies at the preclinical stage.
Through the TURBO module, we expect to determine quantitative data-driven models of disease progression based on the preclinical phase of Alzheimer’s Disease and to identify the most suitable dimensions – among both the biological and the imaging markers – to be integrated in the staging model of Alzheimer’s Disease.
“Understanding Preclinical Alzheimer’s Disease: A Combined MEG-fMRI Approach for Assessing Early Neuronal Network Changes”
Duration: 5 years
The combination of connectivity assessments using both fMRI and MEG modalities is expected to provide key evidence on brain functional alterations in asymptomatic at-risk individuals for Alzheimer’s Disease, stratified according to their biomarker profile.
“Evaluation of retinal amyloid imaging for amyloid screening, for tracking amyloid progression, and for prediction of pathophysiological disease progression, cognitive decline and conversion to prodromal Alzheimer’s Disease”
Duration: 3 years
This research program is conducted in collaboration with NeuroVision Imaging LLC (Sacramento, CA, US), a neuroscience company developing digital imaging and diagnostic solutions for Alzheimer’s Disease and eye care.
Noninvasive retinal imaging may be helpful in the early diagnosis and the treatment of Alzheimer’s Disease resulting in earlier intervention and perhaps noninvasive monitoring, as the Aβ plaques characteristic of the disease may first appear in the eyes.